

EQA round: PAT2/17 - Direct Antiglobulin Test

Dead line: 23.11.2017

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
(1001) DAT (direct Coombs test)				
1	(14) Bio-Rad	1	Negative	1,3 %
		>>> 24	Positive (1+)	32 %
		>>> 15	Positive (2+)	20 %
		> 3	Positive (3+)	3,9 %
	(40) Ortho Clinical Diagnostics	>>> 1	Positive (1+)	1,3 %
		>>> 2	Positive (2+)	2,6 %
	(80) DiaMed	>>> 6	Positive (1+)	7,9 %
		>>> 9	Positive (2+)	12 %
		> 1	Positive (3+)	1,3 %
	(159) Grifols	>>> 9	Positive (1+)	12 %
		>>> 4	Positive (2+)	5,3 %
	(172) Immucor	>>> 1	Positive (1+)	1,3 %
----- Total per sample: n = 76 ----- Success: 99 % -----				
2	(14) Bio-Rad	> 19	Positive (2+)	25 %
		>>> 23	Positive (3+)	30 %
		> 1	Positive (4+)	1,3 %
	(40) Ortho Clinical Diagnostics	>>> 3	Positive (3+)	3,9 %
	(80) DiaMed	> 5	Positive (2+)	6,6 %
		>>> 10	Positive (3+)	13 %
		> 1	Positive (4+)	1,3 %
	(159) Grifols	> 2	Positive (2+)	2,6 %
		>>> 11	Positive (3+)	14 %
	(172) Immucor	> 1	Positive (2+)	1,3 %
----- Total per sample: n = 76 ----- Success: 100 % -----				
Total success: 99 %				

(1002) Sensibilization specificity anti-IgG

1	(0) not specified	> 1	Positive (3+)	2,5 %
	(14) Bio-Rad	>>> 18	Positive (1+)	45 %
		>>> 5	Positive (2+)	13 %
	(80) DiaMed	>>> 5	Positive (1+)	13 %
		>>> 6	Positive (2+)	15 %
	(159) Grifols	>>> 5	Positive (1+)	13 %
----- Total per sample: n = 40 ----- Success: 100 % -----				
2	(0) not specified	>>> 1	Positive (3+)	2,5 %
	(14) Bio-Rad	> 8	Positive (2+)	20 %
		>>> 15	Positive (3+)	38 %
	(80) DiaMed	> 1	Positive (1+)	2,5 %
		> 3	Positive (2+)	7,5 %
		>>> 6	Positive (3+)	15 %
		> 1	Positive (4+)	2,5 %
	(159) Grifols	> 1	Positive (2+)	2,5 %
		>>> 4	Positive (3+)	10 %
----- Total per sample: n = 40 ----- Success: 100 % -----				
Total success: 100 %				

(1003) Sensibilization specificity anti-IgA

1	(14) Bio-Rad	>>> 20	Negative	67 %
	(80) DiaMed	>>> 10	Negative	33 %
----- Total per sample: n = 30 ----- Success: 100 % -----				
2	(14) Bio-Rad	>>> 20	Negative	67 %
	(80) DiaMed	>>> 10	Negative	33 %
----- Total per sample: n = 30 ----- Success: 100 % -----				
Total success: 100 %				

(1004) Sensibilization specificity anti-IgM

1	(14) Bio-Rad	>>> 20	Negative	67 %
	(80) DiaMed	>>> 10	Negative	33 %
----- Total per sample: n = 30 ----- Success: 100 % -----				
2	(14) Bio-Rad	>>> 20	Negative	67 %
	(80) DiaMed	>>> 10	Negative	33 %
----- Total per sample: n = 30 ----- Success: 100 % -----				
Total success: 100 %				

(1005) Sensibilization specificity anti-C3c

1	(14) Bio-Rad	>>> 20	Negative	67 %
	(80) DiaMed	>>> 10	Negative	33 %
----- Total per sample: n = 30 ----- Success: 100 % -----				

Test			N	Result	N _{rel}
Sample	Group				
2	(14) Bio-Rad	>>>	20	Negative	67 %
	(80) DiaMed	>>>	10	Negative	33 %
Total per sample: n = 30		Success: 100 %			
Total success: 100 %					
(1006) Sensibilization specificity anti-C3d					
1	(14) Bio-Rad	>>>	23	Negative	62 %
	(80) DiaMed	>>>	11	Negative	30 %
	(159) Grifols	>>>	3	Negative	8,1 %
Total per sample: n = 37		Success: 100 %			
2	(14) Bio-Rad	>>>	23	Negative	62 %
	(80) DiaMed	>>>	11	Negative	30 %
	(159) Grifols	>>>	3	Negative	8,1 %
Total per sample: n = 37		Success: 100 %			
Total success: 100 %					
(1008) Col. agglut: Quantif. IgG-DAT					
1	(14) Bio-Rad	>	2	Not specified	11 %
		>>>	5	10	26 %
		>	4	Evaluation impossible	21 %
	(80) DiaMed	>	3	Not specified	16 %
		>>>	4	10	21 %
		>	1	Evaluation impossible	5,3 %
Total per sample: n = 19		Success: 100 %			
2	(14) Bio-Rad	>	1	10	5,3 %
		>>>	10	30	53 %
	(80) DiaMed	>>>	8	30	42 %
Total per sample: n = 19		Success: 100 %			
Total success: 100 %					
(1009) Col. agglut: Subclass IgG1 1:1					
1	(14) Bio-Rad	>>>	11	Negative	55 %
			1	Positive (1+)	5,0 %
	(80) DiaMed	>	2	Not specified	10 %
		>>>	6	Negative	30 %
Total per sample: n = 20		Success: 95 %			
2	(14) Bio-Rad	>>>	11	Negative	55 %
			1	Positive (2+)	5,0 %
	(80) DiaMed	>>>	8	Negative	40 %
Total per sample: n = 20		Success: 95 %			
Total success: 95 %					
(1010) Col. agglut: Subclass IgG1 1:100					
1	(14) Bio-Rad	>>>	12	Negative	60 %
	(80) DiaMed	>	2	Not specified	10 %
		>>>	6	Negative	30 %
Total per sample: n = 20		Success: 100 %			
2	(14) Bio-Rad	>>>	12	Negative	60 %
	(80) DiaMed	>>>	8	Negative	40 %
Total per sample: n = 20		Success: 100 %			
Total success: 100 %					
(1011) Col. agglut: Subclass IgG3 1:1					
1	(14) Bio-Rad	>>>	12	Negative	60 %
	(80) DiaMed	>	2	Not specified	10 %
		>>>	6	Negative	30 %
Total per sample: n = 20		Success: 100 %			
2	(14) Bio-Rad	>>>	12	Negative	60 %
	(80) DiaMed	>>>	8	Negative	40 %
Total per sample: n = 20		Success: 100 %			
Total success: 100 %					
(1012) Col. agglut: Subclass IgG3 1:100					
1	(14) Bio-Rad	>>>	12	Negative	60 %
	(80) DiaMed	>	2	Not specified	10 %
		>>>	6	Negative	30 %
Total per sample: n = 20		Success: 100 %			
2	(14) Bio-Rad	>>>	12	Negative	60 %
	(80) DiaMed	>>>	8	Negative	40 %
Total per sample: n = 20		Success: 100 %			
Total success: 100 %					
(1014) Tube test: Quantification IgG-DAT					

Test					
Sample	Group	N	Result	N _{rel}	
1	(14) Bio-Rad	1	titre 8	50 %	
	(173) Sanguin	1	Evaluation impossible	50 %	
	Total per sample: n = 2		Success: 0,00 %		
2	(14) Bio-Rad	1	titre 2	50 %	
	(173) Sanguin	1	titre 2	50 %	
	Total per sample: n = 2		Success: 0,00 %		
Total success: 0,00 %					

(1019) AB0 blood group

1	(14) Bio-Rad	>>>	12	Blood group: AB	25 %
	(40) Ortho Clinical Diagnostics	>>>	2	Blood group: AB	4,2 %
	(64) Exbio Olomouc	>>>	3	Blood group: AB	6,3 %
	(80) DiaMed	>>>	3	Blood group: AB	6,3 %
	(159) Grifols	>>>	11	Blood group: AB	23 %
	(172) Immucor	>>>	4	Blood group: AB	8,3 %
	(173) Sanguin	>>>	8	Blood group: AB	17 %
	(174) IVT Imuno	>>>	5	Blood group: AB	10 %
	Total per sample: n = 48		Success: 100 %		
2	(14) Bio-Rad	>>>	12	Blood group: A	25 %
	(40) Ortho Clinical Diagnostics	>>>	2	Blood group: A	4,2 %
	(64) Exbio Olomouc	>>>	3	Blood group: A	6,3 %
	(80) DiaMed	>>>	3	Blood group: A	6,3 %
	(159) Grifols	>>>	11	Blood group: A	23 %
	(172) Immucor	>>>	4	Blood group: A	8,3 %
	(173) Sanguin	>>>	8	Blood group: A	17 %
	(174) IVT Imuno	>>>	5	Blood group: A	10 %
	Total per sample: n = 48		Success: 100 %		
Total success: 100 %					

(1020) Rh D antigen

1	(6) APR	>>>	1	Negative (RhD-)	2,1 %
	(14) Bio-Rad	>>>	12	Negative (RhD-)	25 %
		>>>	1	Positive (RhD+)	2,1 %
	(40) Ortho Clinical Diagnostics	>>>	2	Negative (RhD-)	4,2 %
	(52) Dynex	>>>	1	Negative (RhD-)	2,1 %
	(80) DiaMed	>>>	3	Negative (RhD-)	6,3 %
	(159) Grifols	>>>	11	Negative (RhD-)	23 %
	(170) Biotest	>>>	1	Negative (RhD-)	2,1 %
	(172) Immucor	>>>	6	Negative (RhD-)	13 %
	(173) Sanguin	>>>	7	Negative (RhD-)	15 %
	(174) IVT Imuno	>>>	2	Negative (RhD-)	4,2 %
	(203) ANTITOXIN	>>>	1	Negative (RhD-)	2,1 %
	Total per sample: n = 48		Success: 98 %		
2	(6) APR	>>>	1	Positive (RhD+)	2,1 %
	(14) Bio-Rad	>>>	13	Positive (RhD+)	27 %
		>>>	2	Positive (RhD+)	4,2 %
	(40) Ortho Clinical Diagnostics	>>>	2	Positive (RhD+)	4,2 %
	(52) Dynex	>>>	1	Positive (RhD+)	2,1 %
	(80) DiaMed	>>>	3	Positive (RhD+)	6,3 %
	(159) Grifols	>>>	11	Positive (RhD+)	23 %
	(170) Biotest	>>>	1	Positive (RhD+)	2,1 %
	(172) Immucor	>>>	6	Positive (RhD+)	13 %
	(173) Sanguin	>>>	7	Positive (RhD+)	15 %
	(174) IVT Imuno	>>>	2	Positive (RhD+)	4,2 %
	(203) ANTITOXIN	>>>	1	Positive (RhD+)	2,1 %
	Total per sample: n = 48		Success: 100 %		
Total success: 98 %					

(1021) Antigen C

1	(14) Bio-Rad	>>>	13	Negative	34 %
	(64) Exbio Olomouc	>>>	1	Negative	2,6 %
	(80) DiaMed	>>>	3	Negative	7,9 %
	(159) Grifols	>>>	13	Negative	34 %
	(172) Immucor	>>>	3	Negative	7,9 %
	(173) Sanguin	>>>	4	Negative	11 %
	(999) another manufacturer	>>>	1	Negative	2,6 %
	Total per sample: n = 38		Success: 100 %		
2	(14) Bio-Rad	>>>	13	Positive	34 %
	(64) Exbio Olomouc	>>>	1	Positive	2,6 %
	(80) DiaMed	>>>	3	Positive	7,9 %
	(159) Grifols	>>>	13	Positive	34 %
	(172) Immucor	>>>	3	Positive	7,9 %

EQA round: PAT2/17 - Direct Antiglobulin Test

Dead line: 23.11.2017

Test

Sample	Group	N	Result	N _{rel}
2	(173) Sanguin	>>> 4	Positive	11 %
	(999) another manufacturer	>>> 1	Positive	2,6 %
Total per sample: n = 38		Success: 100 %		
Total success: 100 %				

(1022) Antigen c

1	(14) Bio-Rad	>>> 13	Positive	34 %
	(64) Exbio Olomouc	>>> 1	Positive	2,6 %
	(80) DiaMed	>>> 3	Positive	7,9 %
	(159) Grifols	>>> 13	Positive	34 %
	(172) Immucor	>>> 3	Positive	7,9 %
	(173) Sanguin	>>> 4	Positive	11 %
	(999) another manufacturer	>>> 1	Positive	2,6 %
Total per sample: n = 38		Success: 100 %		
2	(14) Bio-Rad	>>> 1	Negative	2,6 %
		>>> 12	Positive	32 %
	(64) Exbio Olomouc	>>> 1	Positive	2,6 %
	(80) DiaMed	>>> 3	Positive	7,9 %
	(159) Grifols	>>> 13	Positive	34 %
	(172) Immucor	>>> 3	Positive	7,9 %
	(173) Sanguin	>>> 4	Positive	11 %
	(999) another manufacturer	>>> 1	Positive	2,6 %
Total per sample: n = 38		Success: 97 %		
Total success: 97 %				

(1023) Antigen Cw

1	(0) not specified	1	Not specified	2,9 %
	(14) Bio-Rad	>>> 5	Negative	14 %
	(64) Exbio Olomouc	>>> 1	Negative	2,9 %
	(80) DiaMed	>>> 1	Negative	2,9 %
	(159) Grifols	>>> 14	Negative	40 %
	(170) Biotest	>>> 1	Negative	2,9 %
	(172) Immucor	>>> 3	Negative	8,6 %
	(173) Sanguin	>>> 8	Negative	23 %
	(999) another manufacturer	>>> 1	Negative	2,9 %
Total per sample: n = 35		Success: 97 %		
2	(0) not specified	>>> 1	Negative	2,9 %
	(14) Bio-Rad	>>> 5	Negative	14 %
	(64) Exbio Olomouc	>>> 1	Negative	2,9 %
	(80) DiaMed	>>> 1	Negative	2,9 %
	(159) Grifols	>>> 14	Negative	40 %
	(170) Biotest	>>> 1	Negative	2,9 %
	(172) Immucor	>>> 3	Negative	8,6 %
	(173) Sanguin	>>> 8	Negative	23 %
	(999) another manufacturer	>>> 1	Negative	2,9 %
Total per sample: n = 35		Success: 100 %		
Total success: 97 %				

(1024) Antigen E

1	(14) Bio-Rad	>>> 13	Negative	34 %
	(64) Exbio Olomouc	>>> 1	Negative	2,6 %
	(80) DiaMed	>>> 3	Negative	7,9 %
	(159) Grifols	>>> 13	Negative	34 %
	(172) Immucor	>>> 3	Negative	7,9 %
	(173) Sanguin	>>> 4	Negative	11 %
	(999) another manufacturer	>>> 1	Negative	2,6 %
Total per sample: n = 38		Success: 100 %		
2	(14) Bio-Rad	>>> 1	Not specified	2,6 %
		>>> 12	Negative	32 %
	(64) Exbio Olomouc	>>> 1	Negative	2,6 %
	(80) DiaMed	>>> 2	Negative	5,3 %
		>>> 1	Positive	2,6 %
	(159) Grifols	>>> 13	Negative	34 %
	(172) Immucor	>>> 3	Negative	7,9 %
	(173) Sanguin	>>> 4	Negative	11 %
	(999) another manufacturer	>>> 1	Negative	2,6 %
Total per sample: n = 38		Success: 95 %		
Total success: 95 %				

(1025) Antigen e

1	(14) Bio-Rad	>>> 13	Positive	34 %
---	--------------	--------	----------	------

EQA round: PAT2/17 - Direct Antiglobulin Test

Dead line: 23.11.2017

Test

Sample	Group	N	Result	N _{rel}
1	(64) Exbio Olomouc	>>>	1 Positive	2,6 %
	(80) DiaMed	>>>	3 Positive	7,9 %
	(159) Grifols	>>>	13 Positive	34 %
	(172) Immucor	>>>	3 Positive	7,9 %
	(173) Sanguin	>>>	4 Positive	11 %
	(999) another manufacturer	>>>	1 Positive	2,6 %
	Total per sample: n = 38		Success: 100 %	
2	(14) Bio-Rad	>>>	13 Positive	34 %
	(64) Exbio Olomouc	>>>	1 Positive	2,6 %
	(80) DiaMed	>>>	3 Positive	7,9 %
	(159) Grifols	>>>	13 Positive	34 %
	(172) Immucor	>>>	3 Positive	7,9 %
	(173) Sanguin	>>>	4 Positive	11 %
	(999) another manufacturer	>>>	1 Positive	2,6 %
Total per sample: n = 38		Success: 100 %		
Total success: 100 %				

(1026) Antigen K

1	(14) Bio-Rad	>>>	12 Negative	32 %
	(64) Exbio Olomouc	>>>	2 Negative	5,3 %
	(80) DiaMed	>>>	2 Negative	5,3 %
	(159) Grifols	>>>	14 Negative	37 %
	(172) Immucor	>>>	2 Negative	5,3 %
	(173) Sanguin	>>>	4 Negative	11 %
	(174) IVT Imuno	>>>	1 Negative	2,6 %
	(999) another manufacturer	>>>	1 Negative	2,6 %
Total per sample: n = 38		Success: 100 %		
2	(14) Bio-Rad	>>>	1 Negative	2,6 %
		>>>	11 Positive	29 %
	(64) Exbio Olomouc	>>>	2 Positive	5,3 %
	(80) DiaMed	>>>	2 Positive	5,3 %
	(159) Grifols	>>>	14 Positive	37 %
	(172) Immucor	>>>	2 Positive	5,3 %
	(173) Sanguin	>>>	4 Positive	11 %
	(174) IVT Imuno	>>>	1 Positive	2,6 %
(999) another manufacturer	>>>	1 Positive	2,6 %	
Total per sample: n = 38		Success: 97 %		
Total success: 97 %				

(1027) Antigen k

1	(14) Bio-Rad	>>>	3 Positive	14 %
	(64) Exbio Olomouc	>>>	2 Positive	9,1 %
	(80) DiaMed	>>>	2 Positive	9,1 %
	(159) Grifols	>>>	2 Positive	9,1 %
	(172) Immucor	>>>	2 Positive	9,1 %
	(173) Sanguin	>>>	11 Positive	50 %
Total per sample: n = 22		Success: 100 %		
2	(14) Bio-Rad	>>>	3 Positive	14 %
	(64) Exbio Olomouc	>>>	2 Positive	9,1 %
	(80) DiaMed	>>>	1 Negative	4,5 %
		>>>	1 Positive	4,5 %
	(159) Grifols	>>>	2 Positive	9,1 %
	(172) Immucor	>>>	2 Positive	9,1 %
(173) Sanguin	>>>	11 Positive	50 %	
Total per sample: n = 22		Success: 95 %		
Total success: 95 %				

(1028) Antigen M

1	(6) APR	>>>	1 Positive	4,2 %
	(14) Bio-Rad	>>>	4 Positive	17 %
	(64) Exbio Olomouc	>>>	2 Positive	8,3 %
	(80) DiaMed	>>>	3 Positive	13 %
	(159) Grifols	>>>	3 Positive	13 %
	(172) Immucor	>>>	4 Positive	17 %
	(173) Sanguin	>>>	5 Positive	21 %
	(203) ANTITOXIN	>>>	2 Positive	8,3 %
Total per sample: n = 24		Success: 100 %		
2	(6) APR	>>>	1 Positive	4,2 %
	(14) Bio-Rad	>>>	4 Positive	17 %
	(64) Exbio Olomouc	>>>	2 Positive	8,3 %
	(80) DiaMed	>>>	3 Positive	13 %

Test					
Sample	Group		N	Result	N _{rel}
2	(159) Grifols	>>>	3	Positive	13 %
	(172) Immucor	>>>	4	Positive	17 %
	(173) Sanguin	>>>	5	Positive	21 %
	(203) ANTITOXIN	>>>	2	Positive	8,3 %
	Total per sample: n = 24		Success: 100 %		
Total success: 100 %					
(1029) Antigen N					
1	(6) APR	>>>	1	Positive	4,5 %
	(14) Bio-Rad	>>>	4	Positive	18 %
	(64) Exbio Olomouc	>>>	2	Positive	9,1 %
	(80) DiaMed	>>>	3	Positive	14 %
	(159) Grifols	>>>	3	Positive	14 %
	(172) Immucor	>>>	2	Positive	9,1 %
	(173) Sanguin	>>>	5	Positive	23 %
	(203) ANTITOXIN	>>>	2	Positive	9,1 %
Total per sample: n = 22		Success: 100 %			
2	(6) APR	>>>	1	Negative	4,5 %
	(14) Bio-Rad	>>>	4	Negative	18 %
	(64) Exbio Olomouc	>>>	2	Negative	9,1 %
	(80) DiaMed	>>>	3	Negative	14 %
	(159) Grifols	>>>	3	Negative	14 %
	(172) Immucor	>>>	2	Negative	9,1 %
	(173) Sanguin	>>>	5	Negative	23 %
	(203) ANTITOXIN	>>>	2	Negative	9,1 %
Total per sample: n = 22		Success: 100 %			
Total success: 100 %					
(1030) Antigen S					
1	(6) APR	>>>	1	Negative	4,5 %
	(14) Bio-Rad	>>>	2	Negative	9,1 %
	(64) Exbio Olomouc	>>>	1	Positive	4,5 %
	(80) DiaMed	>>>	2	Negative	9,1 %
	(159) Grifols	>>>	1	Negative	4,5 %
	(172) Immucor	>>>	3	Negative	14 %
	(173) Sanguin	>>>	6	Negative	27 %
Total per sample: n = 22		Success: 95 %			
2	(6) APR	>>>	1	Positive	4,5 %
	(14) Bio-Rad	>>>	3	Positive	14 %
	(64) Exbio Olomouc	>>>	2	Positive	9,1 %
	(80) DiaMed	>>>	1	Positive	4,5 %
	(159) Grifols	>>>	3	Positive	14 %
	(172) Immucor	>>>	6	Positive	27 %
	(173) Sanguin	>>>	6	Positive	27 %
Total per sample: n = 22		Success: 100 %			
Total success: 95 %					
(1031) Antigen s					
1	(14) Bio-Rad	>>>	1	Negative	6,3 %
	(64) Exbio Olomouc	>>>	1	Positive	6,3 %
	(80) DiaMed	>>>	2	Positive	13 %
	(159) Grifols	>>>	1	Positive	6,3 %
	(172) Immucor	>>>	3	Positive	19 %
Total per sample: n = 16		Success: 94 %			
2	(14) Bio-Rad	>>>	2	Positive	13 %
	(64) Exbio Olomouc	>>>	2	Positive	13 %
	(80) DiaMed	>>>	1	Positive	6,3 %
	(159) Grifols	>>>	3	Positive	19 %
	(172) Immucor	>>>	8	Positive	50 %
Total per sample: n = 16		Success: 100 %			
Total success: 94 %					
(1032) Antigen P1					
1	(14) Bio-Rad	>>>	3	Positive	14 %
	(64) Exbio Olomouc	>>>	3	Positive	14 %
	(80) DiaMed	>>>	2	Positive	9,5 %
	(159) Grifols	>>>	2	Positive	9,5 %
	(172) Immucor	>>>	4	Positive	19 %
	(173) Sanguin	>>>	7	Positive	33 %

EQA round: PAT2/17 - Direct Antiglobulin Test

Dead line: 23.11.2017

Test

Sample	Group	N	Result	N _{rel}
Total per sample: n = 21		Success: 100 %		
2	(14) Bio-Rad	>>> 3	Positive	14 %
	(64) Exbio Olomouc	>>> 3	Positive	14 %
	(80) DiaMed	>>> 2	Positive	9,5 %
	(159) Grifols	>>> 2	Positive	9,5 %
	(172) Immucor	>>> 4	Positive	19 %
	(173) Sanguin	>>> 7	Positive	33 %
Total per sample: n = 21		Success: 100 %		
Total success: 100 %				

(1033) Antigen Jka

1	(14) Bio-Rad	>>> 2	Positive	8,0 %
	(52) Dynex	>>> 2	Positive	8,0 %
	(64) Exbio Olomouc	>>> 3	Positive	12 %
	(80) DiaMed	>>> 1	Positive	4,0 %
	(159) Grifols	>>> 4	Positive	16 %
	(172) Immucor	>>> 5	Positive	20 %
	(173) Sanguin	>>> 8	Positive	32 %
Total per sample: n = 25		Success: 100 %		
2	(14) Bio-Rad	>>> 2	Positive	8,0 %
	(52) Dynex	>>> 2	Positive	8,0 %
	(64) Exbio Olomouc	>>> 3	Positive	12 %
	(80) DiaMed	>>> 1	Positive	4,0 %
	(159) Grifols	>>> 4	Positive	16 %
	(172) Immucor	>>> 5	Positive	20 %
	(173) Sanguin	>>> 8	Positive	32 %
Total per sample: n = 25		Success: 100 %		
Total success: 100 %				

(1034) Antigen Jkb

1	(14) Bio-Rad	>>> 2	Positive	8,0 %
	(52) Dynex	>>> 1	Positive	4,0 %
	(64) Exbio Olomouc	>>> 3	Positive	12 %
	(80) DiaMed	>>> 1	Positive	4,0 %
	(159) Grifols	>>> 4	Positive	16 %
	(172) Immucor	>>> 5	Positive	20 %
	(173) Sanguin	>>> 9	Positive	36 %
Total per sample: n = 25		Success: 100 %		
2	(14) Bio-Rad	>>> 2	Positive	8,0 %
	(52) Dynex	>>> 1	Positive	4,0 %
	(64) Exbio Olomouc	>>> 3	Positive	12 %
	(80) DiaMed	>>> 1	Positive	4,0 %
	(159) Grifols	>>> 4	Positive	16 %
	(172) Immucor	>>> 5	Positive	20 %
	(173) Sanguin	>>> 9	Positive	36 %
Total per sample: n = 25		Success: 100 %		
Total success: 100 %				

(1035) Antigen Lea

1	(14) Bio-Rad	>>> 2	Negative	10 %
	(64) Exbio Olomouc	>>> 2	Negative	10 %
	(80) DiaMed	>>> 1	Negative	5,0 %
	(159) Grifols	>>> 3	Negative	15 %
	(172) Immucor	>>> 8	Negative	40 %
	(173) Sanguin	>>> 4	Negative	20 %
Total per sample: n = 20		Success: 100 %		
2	(14) Bio-Rad	>>> 2	Positive	10 %
	(64) Exbio Olomouc	>>> 2	Positive	10 %
	(80) DiaMed	>>> 1	Positive	5,0 %
	(159) Grifols	>>> 3	Positive	15 %
	(172) Immucor	>>> 8	Positive	40 %
	(173) Sanguin	>>> 4	Positive	20 %
Total per sample: n = 20		Success: 100 %		
Total success: 100 %				

(1036) Antigen Leb

1	(14) Bio-Rad	>>> 2	Positive	11 %
	(64) Exbio Olomouc	>>> 2	Positive	11 %
	(80) DiaMed	>>> 1	Positive	5,3 %
	(159) Grifols	>>> 3	Positive	16 %
	(172) Immucor	>>> 7	Positive	37 %
	(173) Sanguin	>>> 4	Positive	21 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT2/17 - Direct Antiglobulin Test

Dead line: 23.11.2017

Test

Sample	Group	N	Result	N _{rel}
Total per sample: n = 19		Success: 100 %		
2	(14) Bio-Rad	>>>	1 Negative	5,3 %
			1 Positive	5,3 %
	(64) Exbio Olomouc	>>>	2 Negative	11 %
	(80) DiaMed	>>>	1 Negative	5,3 %
	(159) Grifols	>>>	3 Negative	16 %
	(172) Immucor	>>>	7 Negative	37 %
	(173) Sanguin	>>>	4 Negative	21 %
Total per sample: n = 19		Success: 95 %		
Total success: 95 %				

st_kl

End of report

Printed: 30.11.2017